enGene Therapeutics Inc. (ENGN)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
enGene Therapeutics Inc. has not issued a press release in this window.
SEC filings
All filings →enGene Therapeutics Inc. has not filed an SEC document in this window.
Insider trades
All insider trades →enGene Therapeutics Inc. has no reported insider trades in the last 90 days.
Institutional holders
All holders →No 13F holdings have been reported for enGene Therapeutics Inc. in this window.
People at enGene Therapeutics Inc.
All people →Quarterly financials
Full financials →No quarterly financials have been ingested for enGene Therapeutics Inc..